Metrics as of 10/15/2026, 08:45 AM (Berlin time), refresh in progress.
Design Therapeutics Stock
Design Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Pratik Shah
- Employees
- 55
- Market cap
- $609 M
- IPO
- 29/03/2021
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily…
Design Therapeutics stock: price history
1D
-0.5%
1W
-16.8%
1M
-28.0%
6M
-23.7%
YTD
+3.7%
1Y
+47.0%
2Y
+88.9%
5Y
-31.7%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~137% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Design Therapeutics
Analyst assessment of Design Therapeutics
PRICE TARGET LOW
US$20.00
CONSENSUS
US$22.33
MEDIAN
US$21.00
PRICE TARGET HIGH
US$26.00
0
STRONG BUY
4
BUY
3
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 04/05/2026
Design Therapeutics stock metrics
P/E
-8.25
P/B
3.01
EV/EBITDA
-8.28
RETURN ON EQUITY
-10.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
55.3%
FLOAT SHARES
34,581,090
AVG. DAILY VOLUME (30D)
709,770
Institutional holders
Comparable stocks
Frequently asked questions about Design Therapeutics stock
What does Design Therapeutics do?
Design Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Pratik Shah, the company employs around 55 people.
The IPO was on 29/03/2021; the stock trades on NASDAQ under the ticker DSGN.
What do analysts say about Design Therapeutics stock?
7 analysts rate the stock, the consensus is Buy (as of 04/05/2026).
The average price target is US$22.33, ranging from US$20.00 to US$26.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does Design Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 137% stronger than usual.
Does Design Therapeutics pay a dividend?
No, Design Therapeutics currently does not pay a dividend.
Which stocks are comparable to Design Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Design Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Design Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.